<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02749630</url>
  </required_header>
  <id_info>
    <org_study_id>GA29469</org_study_id>
    <secondary_id>2015-002512-32</secondary_id>
    <nct_id>NCT02749630</nct_id>
  </id_info>
  <brief_title>A Safety Study of Intravenously Administered UTTR1147A in Healthy Volunteers (HVs), Participants With Ulcerative Colitis (UC), and Participants With Crohn's Disease (CD)</brief_title>
  <official_title>An Observer-Blinded, Placebo-Controlled, Multiple-Ascending, Dose-Escalation Study to Explore the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Repeat Intravenous Administrations of UTTR1147A in Healthy Volunteers and Patients With Ulcerative Colitis and Crohn's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, observer-blinded, placebo-controlled study to evaluate safety,
      tolerability, immunogenicity, and pharmacokinetics of repeat dosing of intravenous (IV)
      UTTR1147A. The study will consist of a repeat dose escalation in HVs, in participants with
      UC, and in participants with CD across multiple sites.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 11, 2016</start_date>
  <completion_date type="Anticipated">February 7, 2020</completion_date>
  <primary_completion_date type="Anticipated">February 7, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with Adverse Events</measure>
    <time_frame>Up to Day 134</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Serum Concentration (Cmax) of UTTR1147A After the First and Last Dose</measure>
    <time_frame>Up to Day 134</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum (Trough) Serum Concentrations (Ctrough) of UTTR1147A Prior to the Second and Last Dose</measure>
    <time_frame>Up to Day 134</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Serum Clearance (CL) of UTTR1147A</measure>
    <time_frame>Up to Day 134</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution (V) of UTTR1147A</measure>
    <time_frame>Up to Day 134</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration vs. Time Curve (AUC) Within a Dose Interval (AUCtau) After the Final Dose of UTTR1147A</measure>
    <time_frame>Up to Day 134</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination Half-Life (t1/2) of UTTR1147A</measure>
    <time_frame>Up to Day 134</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Anti-Therapeutic Antibodies (ATAs) in Serum</measure>
    <time_frame>Up to Day 134</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Ulcerative Colitis</condition>
  <condition>Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>Healthy Volunteer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be given escalating doses of UTTR1147A or Placebo intravenously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ulcerative Colitis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be given escalating doses of UTTR1147A or Placebo intravenously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crohn's Disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be given escalating doses of UTTR1147A or Placebo intravenously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo to UTTR1147A administered intravenously</description>
    <arm_group_label>Healthy Volunteer</arm_group_label>
    <arm_group_label>Ulcerative Colitis</arm_group_label>
    <arm_group_label>Crohn's Disease</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UTTR1147A</intervention_name>
    <description>Escalating doses of intravenously administered UTTR1147A</description>
    <arm_group_label>Healthy Volunteer</arm_group_label>
    <arm_group_label>Ulcerative Colitis</arm_group_label>
    <arm_group_label>Crohn's Disease</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        General inclusion criteria:

          -  No history of malignancy

          -  Documentation of age-appropriate cancer screening based on local/country-specific
             guidelines

          -  For women of childbearing potential: agreement to remain abstinent or use
             contraceptive methods

          -  For men: agreement to remain abstinent or use contraceptive measures and agreement to
             refrain from donating sperm

        For HVs Only:

          -  Age 18 - 50

          -  Body mass index (BMI) between 18 and 32 kilograms per square meter (kg/m2), inclusive

          -  In good health, determined by no clinically significant findings from medical history,
             12-lead electrocardiogram (ECG), and vital signs, and clinical laboratory evaluations
             should be within the reference range for the test laboratory unless deemed not
             clinically significant by the investigator and Sponsor

        For Participants with UC or CD:

          -  Age 18 - 80

          -  Eligible to receive biologic therapy

          -  Disease duration of &gt;/= 12 weeks

          -  Diagnosis of moderate to severe UC or CD

        Exclusion Criteria:

        General exclusion criteria:

          -  History of inflammatory skin disorders

          -  History of any cancer

          -  History of anaphylaxis, hypersensitivity, or drug allergies

          -  History of alcoholism or drug addiction

          -  Positive tests indicating infection for hepatitis C, hepatitis B, or HIV

          -  Use of a non-biologic investigational drug or participation in an investigational
             study with a non-biologic drug within 30 days or 5 half-lives of investigational
             product, whichever is greater, prior to study drug administration

          -  Use of a biologic investigational therapy or participation in an investigational study
             involving biologic therapy within 90 days or 5 half-lives, whichever is greater, prior
             to study drug administration

          -  History or presence of an abnormal ECG that is clinically significant in the
             investigator's opinion

          -  Family history of sudden unexplained death or long QT syndrome

          -  Any acute or chronic condition that would limit the subject's ability to complete
             and/or participate in this clinical study

          -  Pregnant or lactating, or intending to become pregnant for duration of study

        For HVs Only:

          -  Known family history of gastrointestinal (GI) and/or colon cancer

          -  Prior exposure to UTTR1147A

        For Participants with UC or CD:

          -  Significant uncontrolled co-morbidity, such as neurological, cardiac, pulmonary,
             renal, hepatic, endocrine, or GI disorders

          -  History of primary sclerosing cholangitis

          -  Active anti-TNF induced psoriasiform or eczematous lesions

          -  Moderate to severe anemia

          -  Presence of an ileostomy or colostomy

          -  Total proctocolectomy

          -  Positive screening for latent mycobacterial tuberculosis infection

          -  Impaired renal function

          -  Impared hepatic function
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: GA29469 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zeidler Ledcor Centre - University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>CIUSSS-de-l'Est-de-l'Île-de-Montréal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Charité Research Organisation GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Infirmary</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2016</study_first_submitted>
  <study_first_submitted_qc>April 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2016</study_first_posted>
  <last_update_submitted>May 25, 2018</last_update_submitted>
  <last_update_submitted_qc>May 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

